Survival Outcomes of Medullary Thyroid Cancer With and Without Amyloid Deposition
Authors' conclusion
The presence of amyloid in MTC paradoxically associates with lower T stage yet exhibits a trend toward worse cancer-specific mortality. Amyloid deposition alone does not independently influence prognosis. Delayed treatment adversely impacted overall survival.
Study context
- Population
- Patients diagnosed with medullary thyroid cancer (MTC) 2000–2019, Surveillance, Epidemiology, and End Results registry
- Participants
- 2,526 patients
- Exposure
- Amyloid-positive vs amyloid-negative MTC
- Amyloid-positiven = 511
- Amyloid negativen = 2,015reference
- Outcome
- Overall and disease-specific survival
Methodological detailsSEER registry, matched cohorts
- SEER registry
- Matched cohorts
Main finding
As reported in the abstract
P = 0.17
- After adjusting for covariates, amyloid deposition did not independently predict overall survival
- HR = 1.15, 95% CI = 0.91-1.47, P = .25
- After adjusting for covariates, amyloid deposition did not independently predict cancer-specific survival
- HR = 1.30, 95% CI = 0.96-1.77, P = .09
Observational data: associations, not effects.
Further findings
T3/4 stage
P < 0.001
Extrathyroidal extension
P < 0.001
Distal lymph node metastasis
P = 0.020
- Distant metastasis · no difference
- P = 0.98
Distant metastasis
- No difference in distant metastasis rate between groups (14.5% vs 14.4%)
Overall survival: therapy initiated >1 month after diagnosis
- Later therapy initiation, HR for overall survival
- 1.25 (95% CI 1.02-1.54, P = .029)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Survival Outcomes of Medullary Thyroid Cancer With and Without Amyloid Deposition. Endocr Pract. Published 5 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →